NCT00754104View on ClinicalTrials.gov

Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2008

Primary Completion Date

December 31, 2008

Conditions
Solid Tumors
Interventions
DRUG

ABT-869

0.25 mg/kg. daily.

DRUG

Tarceva

150mg, daily.

Sponsors

Lead Sponsor

Abbott

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Abbott

INDUSTRY